The blood culture tests market is projected to reach USD 7.6 billion by 2028 from USD 5.2 billion in 2023, at a CAGR of 8.0% during the forecast period. Growth in this market is majorly driven by the factors such as the growing incidence of sepsis cases and high cost treatment, rising geriatric population, high incidence of bloodstream infections, growing demand for rapid diagnostic techniques and high prevalence of infectious diseases. On the other hand, high cost of automated instruments and lack of trained laboratory technicians are expected to restrain the market growth to some extent in the future.
The prominent players in this market are Becton, Dickinson and Company (US), BioMérieux (France), Thermo Fisher Scientific Inc. (US), Danaher (US), Luminex Corporation (US), Bruker (US), Roche Diagnostics (Switzerland), Iridica (US), Biosystems, Inc (US), BINDER GmBH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio (England), Anaerobe Systems, Inc. (US), Himedia Laboratories Pvt. Ltd. (India), Autobio Diagnostics Co., Ltd. (China), Axiom Laboratories (India), Mikroscan Technologies, Inc. (US), Labotronics Ltd. (UK), Hardy Diagnostics (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany), Nikon Corporation (Japan) and Terumo Corporation (Japan).
To know about the assumptions considered for the study download the pdf brochure
Becton, Dickinson and Company is a renowned multinational company in the field of medical technology. They focus on extensive research, development, manufacturing, and distribution of a diverse array of medical supplies, devices, laboratory equipment, and diagnostic products. Their wide-ranging portfolio caters to the needs of healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD is dedicated to providing innovative solutions that advance healthcare outcomes and elevate the standard of patient care. The company serves in more than 190 countries and employs 77,000 associates.
BioMérieux focuses on delivering advanced in vitro diagnostic solutions that identify the origin of diseases or contamination, thereby enhancing patient health and ensuring consumer safety. Their product portfolio primarily serves the clinical sector, aiding in the diagnosis of infectious diseases, as well as the industrial sector, facilitating the detection of microorganisms in agri-food, pharmaceutical, and cosmetic products. The company operates through four distinct business segments: immunoassays, molecular biology, other ranges, and microbiology. The blood culture test products were offered through microbiology segment. BioMérieux is present in 45 countries and serves more than 160 countries, majorly in North America, South America, Asia, Europe, Africa, and Oceania. with the support of a large network of distributors.
Blood Culture Tests Market by Method (Conventional, Automated), Product (Consumables, Instruments), Technology (Culture, Molecular, Proteomics), Application (Bacteremia, Fungemia), End User (Hospitals, Reference Labs) & Region- Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE